| Literature DB >> 29184847 |
Ankit Kumar Yadav1, Manik Sadora1, Sachin Kumar Singh1, Monica Gulati1, Peddi Maharshi1, Abhinav Sharma1, Bimlesh Kumar1, Harish Rathee1, Deepak Ghai1, Adil Hussain Malik1, Varun Garg1, K Gowthamrajan2.
Abstract
To overcome the limitations of the conventionally used methods for evaluation of orally administered colon-targeted delivery systems, a novel dissolution method using probiotics has been recently reported. In the present study, universal suitability of this medium composed of five different probiotics is established. Different delivery systems - mini tablets, liquisolid compacts, and microspheres coated with different polysaccharides - were prepared and subjected to sequential dissolution testing in medium with and without microbiota. The results obtained from fluid thioglycollate medium (FTM)-based probiotic medium for all the polysaccharide-based formulations showed statistically similar dissolution profile to that in the rat and goat cecal content media. Hence, it can be concluded that the developed FTM-based probiotic medium, once established, may eliminate the need for further animal sacrifice in the dissolution testing of polysaccharide-based colon-targeted delivery system.Entities:
Keywords: Fluid thioglycollate medium; liquisolid compacts; mini tablets; polysaccharides; probiotics
Year: 2017 PMID: 29184847 PMCID: PMC5680623 DOI: 10.4103/japtr.JAPTR_70_17
Source DB: PubMed Journal: J Adv Pharm Technol Res ISSN: 0976-2094
Unit formula composition of prepared tablets
Unit formula composition for Liquisolid tablets
List of ingredients and their quantities used in formulation of SFZ microspheres
Composition of FTM (Formula/L)
Composition of 325 mg of probiotic blend
Figure 1(a) Mean (±standard deviation) % cumulative release of sulfasalazine from tablets using compendial method. (b) Mean (±standard deviation) % cumulative release of sulfasalazine from tablets using 5.0% w/v human fecal slurries. (c) Mean (±standard deviation) % cumulative release of sulfasalazine from tablets using 4.5% w/v rat cecal contents. (d) Mean (±standard deviation) % cumulative release of sulfasalazine from tablets using 4.5% goat cecal contents. (e) Mean (±standard deviation) % cumulative release of sulfasalazine from tablets using probiotic medium
Figure 2Mean (±standard deviation) % cumulative release of sulfasalazine from liquisolid tablets using different media
Figure 3Mean (±standard deviation) % cumulative release of sulfasalazine from microspheres using different media